Targeted therapy for squamous cell carcinoma of the head and neck.

Ibrahim T. Aldoss, Apar Kishor P Ganti

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Targeted agents have emerged as novel drugs in the oncology field based on our understanding of the biology of individual malignancies, and have had a promising impact in several tumors. Squamous cell carcinoma of the head and neck (SCCHN) is a common disease with little progress made in survival over the past few decades. SCCHN is characterized by overexpression of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), both of which appear to have a prognostic value. Hence these receptors and their downstream pathways make attractive therapeutic targets. This review discusses targeted therapies currently being evaluated for their role in squamous cell carcinoma of the head and neck.

Original languageEnglish (US)
Pages (from-to)157-166
Number of pages10
JournalJournal of the Egyptian National Cancer Institute
Volume21
Issue number2
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Cerebral Palsy
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Neoplasms
Therapeutics
Pharmaceutical Preparations
Carcinoma, squamous cell of head and neck

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeted therapy for squamous cell carcinoma of the head and neck. / Aldoss, Ibrahim T.; Ganti, Apar Kishor P.

In: Journal of the Egyptian National Cancer Institute, Vol. 21, No. 2, 01.01.2009, p. 157-166.

Research output: Contribution to journalReview article

@article{5beec99b05b7428f86b86e08f5dedb4a,
title = "Targeted therapy for squamous cell carcinoma of the head and neck.",
abstract = "Targeted agents have emerged as novel drugs in the oncology field based on our understanding of the biology of individual malignancies, and have had a promising impact in several tumors. Squamous cell carcinoma of the head and neck (SCCHN) is a common disease with little progress made in survival over the past few decades. SCCHN is characterized by overexpression of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), both of which appear to have a prognostic value. Hence these receptors and their downstream pathways make attractive therapeutic targets. This review discusses targeted therapies currently being evaluated for their role in squamous cell carcinoma of the head and neck.",
author = "Aldoss, {Ibrahim T.} and Ganti, {Apar Kishor P}",
year = "2009",
month = "1",
day = "1",
language = "English (US)",
volume = "21",
pages = "157--166",
journal = "Journal of the Egyptian National Cancer Institute",
issn = "1110-0362",
publisher = "National Cancer Institute",
number = "2",

}

TY - JOUR

T1 - Targeted therapy for squamous cell carcinoma of the head and neck.

AU - Aldoss, Ibrahim T.

AU - Ganti, Apar Kishor P

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Targeted agents have emerged as novel drugs in the oncology field based on our understanding of the biology of individual malignancies, and have had a promising impact in several tumors. Squamous cell carcinoma of the head and neck (SCCHN) is a common disease with little progress made in survival over the past few decades. SCCHN is characterized by overexpression of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), both of which appear to have a prognostic value. Hence these receptors and their downstream pathways make attractive therapeutic targets. This review discusses targeted therapies currently being evaluated for their role in squamous cell carcinoma of the head and neck.

AB - Targeted agents have emerged as novel drugs in the oncology field based on our understanding of the biology of individual malignancies, and have had a promising impact in several tumors. Squamous cell carcinoma of the head and neck (SCCHN) is a common disease with little progress made in survival over the past few decades. SCCHN is characterized by overexpression of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), both of which appear to have a prognostic value. Hence these receptors and their downstream pathways make attractive therapeutic targets. This review discusses targeted therapies currently being evaluated for their role in squamous cell carcinoma of the head and neck.

UR - http://www.scopus.com/inward/record.url?scp=79952278090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952278090&partnerID=8YFLogxK

M3 - Review article

VL - 21

SP - 157

EP - 166

JO - Journal of the Egyptian National Cancer Institute

JF - Journal of the Egyptian National Cancer Institute

SN - 1110-0362

IS - 2

ER -